On the stock market since 2018, it operates in the world of health and science. It has 48 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $19.6M a year. A small number, but proof the product has real buyers.
The average analyst price target is $6.00 — 5,794% above today’s price.
A loss of $29.9M against $19.6M in annual sales.
The stock sits at $0.10. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, OBSV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OBSV is a high-risk stock — not yet profitable, and its future rides on its product catching on.